Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
8.81
+0.07 (0.80%)
At close: Aug 1, 2025, 4:00 PM
8.84
+0.03 (0.34%)
After-hours: Aug 1, 2025, 7:56 PM EDT
DFS Revenue
Viatris had revenue of $3.25B in the quarter ending March 31, 2025, a decrease of -11.17%. This brings the company's revenue in the last twelve months to $14.33B, down -6.71% year-over-year. In the year 2024, Viatris had annual revenue of $14.74B, down -4.46%.
Revenue (ttm)
$14.33B
Revenue Growth
-6.71%
P/S Ratio
0.73
Revenue / Employee
$447,819
Employees
32,000
Market Cap
10.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
VTRS News
- 2 days ago - Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference - PRNewsWire
- 12 days ago - 10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts - Market Watch
- 16 days ago - Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga
- 16 days ago - Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barrons
- 16 days ago - Viatris eye therapy fails to meet late-stage trial goal - Reuters
- 16 days ago - Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PRNewsWire
- 18 days ago - Viatris: A Contrarian Bet With Virtually No Downside - Seeking Alpha
- 23 days ago - Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys - Seeking Alpha